NorthRock Partners LLC Has $571,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NorthRock Partners LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 90.0% in the fourth quarter, HoldingsChannel reports. The firm owned 802 shares of the biopharmaceutical company’s stock after purchasing an additional 380 shares during the period. NorthRock Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $571,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Willner & Heller LLC increased its holdings in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares in the last quarter. OLD Second National Bank of Aurora increased its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after purchasing an additional 15 shares in the last quarter. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 18 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Bank of America lowered their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. Guggenheim reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating for the company in a research note on Thursday, May 1st. Finally, UBS Group reduced their price objective on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $890.60.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ:REGN opened at $594.32 on Friday. The stock has a market cap of $64.17 billion, a price-to-earnings ratio of 15.53, a PEG ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $520.50 and a 12-month high of $1,211.20. The business’s 50 day moving average is $599.96 and its 200 day moving average is $684.64.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the business posted $9.55 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.